Pembrolizumab for advanced throat cancer to avoid laryngectomy
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing clinical trials.
This trial tests whether a drug called pembrolizumab (Keytruda) can help people with advanced throat cancer avoid removal of the voice box. You may be eligible if you have a specific type of larynx or hypopharynx cancer that hasn't been treated with radiation or immunotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of throat cancer called squamous cell carcinoma of the larynx or hypopharynx.
- Your cancer must be at stage III, IVA, or IVB, and your doctors believe surgery to remove the larynx is an option.
- You must have a fresh tumor biopsy that shows a specific protein (PD-L1) at a certain level (CPS ≥ 1).
- You cannot have had prior treatment with immunotherapy drugs like pembrolizumab or radiation therapy.
- You must be in good general health (ECOG score 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
This trial is testing a drug called tislelizumab combined with standard chemotherapy to help people with advanced throat cancer keep their voice box (larynx). The goal is to shrink the tumor enough so surgery may not be needed.
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
This trial tests whether giving a type of immunotherapy (PD-1 inhibitor) together with chemotherapy before surgery can help treat advanced laryngeal and hypopharyngeal squamous cell carcinoma. It aims to improve outcomes for patients whose cancer hasn't spread to distant organs.
This trial tests adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy before surgery for advanced laryngeal or hypopharyngeal cancer. The goal is to see if this combination shrinks tumors more and improves outcomes for patients who need their entire voice box removed.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
Hear when a new Hypopharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.